P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans

International Journal of Clinical Pharmacology and Therapeutics

Volumn 38, Issue 4, 2000, Pages 161-167

  Schwarz, U I ^a,c   Gramatte T ^b   Krappweis, J ^a   Oertel, R ^a   Kirch, W ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b APOGEPHA Arzneimittel GmbH   (Germany)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug drug interaction; Erythromycin; P glycoprotein; Pharmacokinetics; blocker talinolol

Indexed keywords

ERYTHROMYCIN; PLACEBO; TALINOLOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INTERACTION; DRUG URINE LEVEL; HUMAN; MALE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL;

EID: 0034111043     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP38161     Document Type: Article

References (38)

1. Benet LZ, Zia-Amirhosseini P 1995 Basic principles of pharmacokinetics. Toxicol Pathol 23: 115-123
2. Berndt A, Gramatté T, Kirch W 1996 Digoxin-erythromycin interaction: in vitro evidence for competition for intestinal P-glycoprotein (Abstract). J Clin Pharmacol 36: 848
3. Borst P, Schinkel AH, Smit JJ, Wagenaar E, Van Deemter L, Smith AJ, Eijdems EW, Baas F, Zaman GJ 1993 Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 60: 289-299
4. Brockmeier D, Lückel G 1991 HOKREP-PC (Version 1.05.00) An interactive program package for the analysis of pharmacokinetic data. User manual. Internal report, Doc. No. 011502, Hoechst AG, Frankfurt/Main
5. Cavet ME, West M, Simmons NL 1996 Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118: 1389-1396
6. Cordon-Cardo CO, JP OB, Boccia J, Casals D, Bertino JR, Melamed MR 1990 Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. J Histochem Cytochem 38: 1277-1287
7. Dobkin, JF, Saha JR, Butler VP, Neu HC, Lindenbaum J 1983 Digoxin-inactivating bacteria: identification in human gut flora. Science 220: 325-327
8. Freeman, DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, Stiller CR 1987 Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol 23: 776-778
9. Friedman HS, Bonvetre MV 1982 Erythromycin-induced digoxin toxicity. Chest 82: 202
10. Ginsburg CM, Eichenwald HF 1976 Erythromycin: a review of its uses in pediatric practice. J Pediatr 89: 872-884
11. Gottesman MM, Pastan I 1993 Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427
12. Gramatté T, Oertel R, Terhaag B, Kirch W 1996 Direct demonstration of small intestinal secretion and site-dependent absorption of the beta-blocker talinolol in humans. Clin Pharmacol Ther 59: 541-549
13. Gramatté T, Oertel R 1999 Intestinal secretion of intavenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 66: in press
14. Gupta SK, Bakran A, Johnson RW, Rowland M 1988 Erythromycin enhances the absorption of cyclosporin. Br J Clin Pharmacol 25: 401-402
15. Gupta SK, Bakran A, Johnson RW, Rowland M 1989 Cyclosporin-erythromycin interaction in renal transplant patients. Br J Clin Pharmacol 27: 475-481
16. Haustein KO, Fiehring H, Oltmanns G, Femmer K 1979 On the clinical pharmacology of talinolol, a new beta-1-adrenoceptor blocking agent. Int J Clin Pharmacol Biopharm 17: 465-470
17. Hofsli E, Nissen-Meyer J 1989 Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. Int J Cancer 44: 149-154
18. Hofsli E, Nissen-Meyer J 1990 Reversal of multidrug resistance by lipophilic drugs. Cancer Res 50: 3997-4002
19. Hunter J, Hirst BH 1997 Intestinal secretion of drugs. The role of P-glycoprotcin and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 25: 129-157
20. Ignoffo RJ, Kim LE 1991 Erythromycin and cyclosporine drug interaction. DICP 25: 30-31
21. Keshavarzian A, Isaac RM 1993 Erythromycin accelerates gastric emptying of indigestible solids and transpyloric migration of the tip of an enteral feeding tube in tasting and fed states. Am J Gastroenterol 88: 193-197
22. Lehtola J, Jauhonen P, Kesaniemi A, Wikberg R, Gordin A 1990 Effect of erythromycin on the oro-caecal transit time in man. Eur J Clin Pharmacol 39: 555-558
23. Lindenbaum J, Rund DG, Butler VP Jr, Tse-Eng D, Saha JR 1981 Inactivation of digoxin by the gut flora: reversal by antibiotic therapy. N Engl J Med 305: 789-794
24. Makhey VD, Guo A, Norris DA, Hu P, Yan J, Sinko PJ 1998 Characterization of the regional intestinal kinetics of drug efflux in rat and human intestine and in Caco-2 cells. Pharm Res 15: 1160-1167
25. Maxwell DL, Gilmour-White SK, Hall MR 1989 Digoxin toxicity due to interaction of digoxin with erythromycin. Br Med J 298: 572
26. Mayer U, Wagenaar E, Beijnen JH, Smith JW, Meijer DK, van Asperen J, Borst P, Schinkel AH 1996 Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol 119: 1038-1044
27. Oertel R, Richter K, Trausch B, Berndt A, Gramatté T, Kirch W 1994 Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. J Chromatogr B Biomed Appl 660: 353-363
28. Oertel R, Schwarz U, Kirch W 1998 In-vitro-Untersuchungen zur Wechselwirkung von Talinolol mit verschiedenen Erythromycinpräparaten und -rein-substanzen. Pharmazie 53: 277-278
29. Periti P, Mazzei T, Mini E, Novelli A 1989 Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part 1). Clin Pharmacokinet 16: 193-214
30. Peters U, Falk LC, Kalman SM 1978 Digoxin metabolism in patients. Arch Intern Med 138: 1074-1076
31. Schwarz UI, Gramatté J, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W 1999 Unexpected effect of verapamil on oral bioavailability of the β-blocker talinolol in humans. Clin Pharmacol Ther 65: 283-290
32. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P 1998 P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36: 16-24
33. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R 1992 Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263: 840-845
34. Terhaag B, Richter K, Potter H 1983 Zur Pharmakokinetik von Talinolol (Cordanum) beim Menschen nach oraler Gabe. Pharmazie 38: 568-569
35. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC 1987 Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738
36. Trausch B, Oertel R, Richter K, Gramatté T 1995 Disposition and bioavailability of the beta-1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 16: 403-414
37. Watterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P 1996 Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharm Res 13: 514-522
38. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, Wacher VJ 1995 Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58: 492-497